Showing 5551-5560 of 5909 results for "".
- Alnylam and Regeneron to Partner for RNAi Treatmentshttps://modernod.com/news/alnylam-regeneron-to-partner-for-rnai-treatments/2476457/Alnylam Pharmaceuticals and Regeneron Pharmaceuticals have agreed to jointly develop treatments for eye and central nervous system diseases using gene-silencing technology RNA interference (RNAi). Regeneron will make a $400 million upfront payment to Alnylam and also purchase $400 mill
- Allegro Ophthalmics Appoints Marc Carlson and Rebecca Colbert to Board of Directorshttps://modernod.com/news/allegro-ophthalmics-appoints-marc-carlson-and-rebecca-colbert-to-board-of-directors/2476454/Allegro Ophthalmics announced that two new independent members—Marc Carlson and Rebecca Colbert—have been appointed to the company’s Board of Directors with Ms. Colbert serving as Chairperson of the Board’s Audit Committee. Bringing extensive executive level commercial and financial leadership ex
- Nidek Launches the ARK-F/AR-F Auto Refractometerhttps://modernod.com/news/nidek-launches-the-ark-f-ar-f-auto-refractometer/2476446/Nidek has announced the launch of the ARK-F/AR-F Keratometer and Auto Refractometer. The ARK-F/AR-F features fully-automatic measurement. By placing the chin on the chinrest, the new Nidek eye detection camera
- A Soft Spot for Stem Cells Helps Cornea Healinghttps://modernod.com/news/a-soft-spot-for-stem-cells-helps-cornea-healing/2476436/New research led by scientists at Newcastle University, UK, reveals a potential revolutionary way to treat eye injuries and prevent blindness—by softening the tissue hosting the stem cells which then helps repair wounds inside the body. The team discovered that the simple application of a
- Ocutrx Vision Technologies Receives Second Patent for Augmented Reality Glasses Eye Tracking Technologyhttps://modernod.com/news/ocutrx-vision-technologies-receives-second-patent-for-augmented-reality-glasses-eye-tracking-technology/2476434/Ocutrx Vision Technologies, a manufacturer of augmented reality (AR) glasses, announced the issuance of the company’s second US patent, which will protect the company’s unique eye tracking technology for patients with macular degeneration and other low vision conditions. The patent applies to bot
- Allergan and Molecular Partners Announce Topline Safety Results From MAPLE Study of Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol/2476430/Allergan and Molecular Partners announced topline safety results from MAPLE, a 28-week open-label study which enrolled 123 age-related neovascular macular degeneration (AMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process. In this single arm study, trea
- Stealth BioTherapeutics Doses First Patient in Phase 2 Study of Elamipretide for the Treatment of Dry AMDhttps://modernod.com/news/stealth-biotherapeutics-announces-dosing-of-first-patient-in-phase-2-study-of-elamipretide-for-the-treatment-of-dry-amd/2476423/Stealth BioTherapeutics announced that it has dosed the first patient in ReCLAIM-2, a phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy. “People with dry AMD can ultimately lose central vision. However, long before that
- Quantel Medical Receives FDA Approval for ABSolu Ultrasound Platformhttps://modernod.com/news/quantel-medical-receives-fda-approval-for-absolu-ultrasound-platform/2476415/Quantel Medical announced that it has received approval from the FDA for the new A/B/S ultrasound platform: ABSolu. The ABSolu includes a new 5 ring annular technology 20MHz B probe that increases the depth of
- Alkahest Presents Positive Phase 2a Study Results of AKST4290 for Treatment-Naïve Wet AMDhttps://modernod.com/news/alkahest-presents-positive-phase-2a-study-results-of-akst4290-for-treatment-naive-wet-amd/2476414/Alkahest shared results from its open label study, ALK4290-201. The data were delivered during a podium presentation as the Abstract Winner of the First-time Presentations of Clinical Trials and Late Breakers session at the 2019 Retina World Congress. The study evaluated the therapeutic effect an
- Novartis Plans for Alcon Spin-Off on April 9, 2019https://modernod.com/news/novartis-plans-for-alcon-spin-off-on-april-9-2019/2476408/Novartis confirmed that conditions needed for the 100% spin-off of the Alcon eye care business have been met, and the spinoff is expected to be completed on April 9, 2019. Each Novartis shareholder will receive 1 Alcon share for every 5 Novartis shares/American Deposit